NCT03817476View on ClinicalTrials.gov

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

May 28, 2019

Study Completion Date

May 28, 2019

Conditions
Healthy
Interventions
DRUG

BI 425809 (Treatment T1)

Intended commercial formulation tablet from batch 1 (iCF1)

DRUG

BI 425809 (Treatment T2)

Intended commercial formulation tablet from batch 2 (iCF2)

DRUG

BI 425809 (Treatment R)

Trial formulation 2 tablet (TF2)

Trial Locations (1)

88397

Humanpharmakologisches Zentrum Biberach, Biberach

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03817476 - A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood | Biotech Hunter | Biotech Hunter